Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
propofol + fentanyl + lidocaine
- Development stage
- Unknown
- Lead developer
- University of Medicine and Pharmacy "Iuliu Hatieganu"
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Propofol + fentanyl + lidocaine is a multi-drug anesthetic and analgesic regimen being investigated for its potential therapeutic impact on perioperative outcomes in patients with hepatocellular carcinoma (HCC). In this combination, propofol acts as a short-acting intravenous sedative-hypnotic via positive allosteric modulation of the GABA-A receptor, while fentanyl serves as a potent synthetic opioid analgesic targeting mu-opioid receptors. Lidocaine, a sodium channel blocker, is added to the regimen not only for its anesthetic properties but also for its potential to modulate the inflammatory response and inhibit NETosis (neutrophil extracellular trap formation). The regimen is specifically being studied by the Iuliu Hatieganu University of Medicine and Pharmacy in the context of radiofrequency ablation (RFA) for HCC to evaluate whether the suppression of NETosis can reduce tumor recurrence and improve overall survival.
- Other names
- propofol + fentanyl + lidocaine regimenPF-L group
02
Targets
GABRR (GABA-A receptor subunit rho)MOR (Mu opioid receptor)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on propofol + fentanyl + lidocaine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on propofol + fentanyl + lidocaine.